Pfizer
NEWS
As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
The ointment had previously been approved for patients ages two and above in 2016.
Pfizer had a good day Wednesday with the announcement of positive results from two Phase III trials, one in moderate to severe atopic dermatitis and one in pneumococcal disease.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
The two companies will focus on BioNTech’s BNT162, an mRNA-based vaccine candidate.
The companies jointly announced that their Phase III JAVELIN Head and Neck 100 trial of Bavencio (avelumab) with chemoradiotherapy for untreated locally advanced squamous cell carcinoma of the head and neck was unlikely to hit the primary endpoint.
It was a very busy week for clinical trial news. Here’s a look.
Two months after Pfizer and Astellas’ Xtandi won regulatory approval for a new indication in prostate cancer, the companies have released positive new data in another type of prostate cancer.
JOBS
IN THE PRESS